Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma

Neuro-Oncology

Volumn 16, Issue 3, 2014, Pages 392-399

  Tabouret, Emeline ^a,b   Boudouresque, Françoise ^a,b,c   Barrie, Maryline ^a   Matta, Mona ^a   Boucard, Celine ^a   Loundou, Anderson ^a   Carpentier, Antoine ^d,e   Sanson, Marc ^f,g   Metellus, Philippe ^b   Figarella Branger, Dominique ^a,b   Ouafik, L'Houcine ^a,b,h   Chinot, Olivier ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^d Service de Neurologie   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSERM   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h HÔPITAL NORD   (France)

Author keywords

bevacizumab; high grade glioma; matrix metalloproteinase 2; matrix metalloproteinase 9; predictive factor

Indexed keywords

BEVACIZUMAB; HIGH GRADE GLIOMA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PREDICTIVE FACTOR;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894246282     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not226     Document Type: Article

References (27)

1. VanMeter ME,KimES. Bevacizumab:current updates in treatment. Curr Opin Oncol. 2010;22(6):586-591.
2. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-844.
3. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
4. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28(4):334-340.
5. Duda DG, Ancukiewicz M, Jain RK. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol. 2010;28(2):183-185.
6. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11(12):1172-1183.
7. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28(2):193-201.
8. Batchelor TT,DudaDG, di TomasoE, et al. Phase II studyof cediranib,an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010; 28(17):2817-2823.
9. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
10. Ouafik L, Sauze S, Boudouresque F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol. 2002; 160(4):1279-1292.
11. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J ClinOncol. 2008;26(22):3743-3748.
12. Prados M, Cloughesy T, Samant M, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011;13(1):143-151.
13. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26(2):271-278.
14. Raizer JJ,GrimmS, ChamberlainMC, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116(22):5297-5305.
15. Niers TM, Richel DJ, Meijers JC, Schlingemann RO. Vascular endothelial growthfactor in the circulation in cancerpatientsmaynotbearelevant biomarker. PLoS One. 2011;6(5):e19873.
16. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27(31):5287-5297.
17. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008;14(8):2378-2386.
18. Papathoma AS, Petraki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res. 2000;20(3B):2009-2013.
19. Jaalinoja J, Herva R, Korpela M, Hoyhtya M, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neurooncol. 2000;46(1):81-90.
20. Colin C, Voutsinos-Porche B, Nanni I, et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol. 2009; 118(6):745-754.
21. Brell M, Ibanez J, Felpete A, Burguera B, Frontera M, Couce ME. Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas. Brain Tumor Pathol. 2011;28(2):137-144.
22. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans andmice. Neuro Oncol. 2010;12(3):233-242.
23. Takano S, Mashiko R, Osuka S, Ishikawa E, Ohneda O, Matsumura A. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol. 2010;27(2):89-94.
24. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(14):4589-4599.
25. Du R, Petritsch C, Lu K, et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008;10(3):254-264.
26. Tremblay P, Beaudet MJ, Tremblay E, Rueda N, Thomas T, Vallieres L. Matrix metalloproteinase 2 attenuates brain tumour growth, while promoting macrophage recruitment and vascular repair. J Pathol. 2011;224(2):222-233.
27. Carmeliet P, Jain RK. Molecularmechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298-307.